We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
Cap. Flow
+$198M
Cap. Flow %
32.7%
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$118M
2
TNGX icon
Tango Therapeutics
TNGX
+$67.4M
3
RVMD icon
Revolution Medicines
RVMD
+$23.6M
4
PHVS icon
Pharvaris
PHVS
+$18.2M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.1M

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$7.49M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.63M
3
PCVX icon
Vaxcyte
PCVX
+$4.27M
4
SLNO
Soleno Therapeutics
SLNO
+$3.88M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
101
Denali Therapeutics
DNLI
$3.26B
– –
-35,286
Closed -$677K
EWTX icon
102
Edgewise Therapeutics
EWTX
$4.27B
– –
-11,701
Closed -$369K
INBX icon
103
Inhibrx
INBX
$1.47B
– –
-2,482
Closed -$167K
IRON icon
104
Disc Medicine
IRON
$2.5B
– –
-3,231
Closed -$207K
KALV
105
DELISTED
KalVista Pharmaceuticals
KALV
– –
-128,487
Closed -$2.59M
LLY icon
106
Eli Lilly
LLY
$1.05T
– –
-720
Closed -$662K
MGNX icon
107
MacroGenics
MGNX
$238M
– –
-13,387
Closed -$38.7K
MLYS icon
108
Mineralys Therapeutics
MLYS
$2.29B
– –
-69,571
Closed -$1.88M
NKTR icon
109
Nektar Therapeutics
NKTR
$1.95B
– –
-4,300
Closed -$309K
NTLA icon
110
Intellia Therapeutics
NTLA
$1.65B
– –
-31,500
Closed -$404K
NUVL
111
DELISTED
Nuvalent
NUVL
– –
-2,072
Closed -$212K
OCUL icon
112
Ocular Therapeutix
OCUL
$2.12B
– –
-31,296
Closed -$265K
PEPG icon
113
PepGen
PEPG
$179M
– –
-59,500
Closed -$105K
REPL icon
114
Replimune Group
REPL
$1.16B
– –
-120,400
Closed -$921K
SLNO
115
DELISTED
Soleno Therapeutics
SLNO
– –
-115,770
Closed -$3.88M
TYRA icon
116
Tyra Biosciences
TYRA
$1.5B
– –
-195,685
Closed -$7.49M
UTHR icon
117
United Therapeutics
UTHR
$20.4B
– –
-1,128
Closed -$669K
VSTM icon
118
Verastem
VSTM
$701M
– –
-123,400
Closed -$654K
CLYM
119
Climb Bio
CLYM
$670M
– –
-130,654
Closed -$895K
SEPN
120
Septerna Inc
SEPN
$1.76B
– –
-11,445
Closed -$275K
MAZE
121
Maze Therapeutics
MAZE
$1.45B
– –
-30,707
Closed -$917K
WHWK
122
Whitehawk Therapeutics
WHWK
$213M
– –
-54,296
Closed -$187K
1 2 3 4
5

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.

  • Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
  • Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
  • Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
  • Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
  • Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
  • Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
  • Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.